Appointment of Mr. Navjyoti Kumar Jha as internal auditor of the company for the F.Y. 2026-27.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Genomic Valley Biotech Ltd reported FY 2026 standalone audited results. Revenue from operations declined marginally to Rs 26.36 lakh from Rs 26.75 lakh in FY 2025. The company swung to a net loss of Rs 8.35 lakh from a profit of Rs 3.03 lakh in the previous year. Total expenses stood at Rs 2.62 crore while cash generated from operations was Rs 4.52 lakh. The Board also approved the appointment of Mr. Navjyoti Kumar Jha as Internal Auditor for FY 2026-27. The statutory auditor M/s Andros & Co. issued an unmodified (clean) audit opinion on the financial statements.
The company swung from profit to loss in FY 2026, indicating deteriorating financial performance. The clean audit opinion provides assurance on financial reporting quality. The appointment of the internal auditor is a routine governance matter.